Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 1, 2000, Pages 53-57

  Lassen, Michael R ^a,b   Borris, Lars C ^a   Jensen, Hans P ^a   Poulsen, Kristian Aa ^a   Ejstrud, Per ^a   Andersen, Birthe S ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

Hip surgery; Low molecular weight heparin; Trial

Indexed keywords

DICOUMAROL; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; HIP ARTHROPLASTY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION;

EID: 0033970637     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600109     Document Type: Article

References (11)

1. Prevention of venous thromboembolism. International consensus statement. Int Angiol 1997;16:3-38.
2. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-38.
3. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144.
4. Zachrisson BE, Jansen H. Phlebographic signs in fresh postoperative venous thrombosis of the lower extremity. Acta Radiol (Diagn) 1973;14:82-96.
5. Casagrande JT, Pike MC, Smith PG. The power function of the exact test for comparing two binominal distributions. Appl Stat 1978;27:176-180.
6. Mätzsch T, Bergqvist D, Fredin H, Hedner U. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand 1988;543(suppl):80-84.
7. Mätzsch T, Bergqvist D, Fredin H, et al. Comparison of the thromboprophylactic effect of low molecular weight heparin versus dextran in total hip replacement. Thromb Haemorrh Disorders 1991; 3:25-29.
8. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990;16:207-216.
9. Prentice C. Thromboprophylaxis in elective orthopaedic surgery - what is the purpose? J Bone Joint Surg 1997;79:896-899.
10. Bulstrode CJK. Commentary on thromboprophylaxis in hip replacement surgery. Acta Orthop Scand 1998;69:343-344.
11. Planes A, Vochelle N, Ferru J, et al. Enoxaparin low molecular weight heparin its use in the prevention of deep venous thrombosis following total hip replacement. Hemostasis 1986;16:152-158.